Q-omics provides the consensus-scored MAB21L2 profile across patient tissues and cancer cell-line models. MAB21L2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MAB21L2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MAB21L2 RNA expression shows 15,255 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, THCA, and THYM as cancer lineages where MAB21L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAB21L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAB21L2 survival associations across molecular data types. MAB21L2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAB21L2 RNA expression–survival associations across cancer types. High MAB21L2 expression shows unfavorable associations in LGG, ACC, LUSC and OV, but favorable associations in THCA and SCLC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MAB21L2 RNA expression.
This table summarizes MAB21L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAB21L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAB21L2 shows lower tumor expression in THCA, KIRC, COAD, LUSC, STAD and KICH. The THCA box plot shows higher MAB21L2 RNA expression in normal versus tumor tissue (log2 FC = −1.668, t-test p < 0.001).
This table shows molecular features associated with MAB21L2 in patient tissues and cancer cell lines. In patient samples, MAB21L2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAB21L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
